LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Отворен

СекторЗдравеопазване

56.91 1.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

55.84

Максимум

57.03

Ключови измерители
By Trading Economics
Приходи	1.6B 2.7B
Продажби	-1B 11B
P/E Средно за сектора	15.726 51.415
EPS	1.58
Дивидентна доходност	4.45
Марж на печалбата	23.309
Служители	32,500
EBITDA	1.5B 3.7B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+13.89% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	4.45% 2.34%
Следващи печалби	30.07.2026 г.
Следваща дата на дивидент	31.07.2026 г.
Следваща дата на екс-дивидент	2.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.3B 114B
Предишно отваряне	55.14
Предишно затваряне	56.91

Настроения в новините

By Acuity

43%

57%

138 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

N/A / 50.57 Подкрепа & съпротива

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.05.2026 г., 06:42 ч. UTC

Значими двигатели на пазара

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30.04.2026 г., 11:14 ч. UTC

Печалби

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

5.05.2026 г., 18:12 ч. UTC

Печалби

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5.05.2026 г., 13:54 ч. UTC

Печалби

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14.04.2026 г., 14:13 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 12:57 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 11:19 ч. UTC

Печалби

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14.04.2026 г., 10:34 ч. UTC

Печалби

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

6.02.2026 г., 12:35 ч. UTC

Печалби

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

5.02.2026 г., 15:25 ч. UTC

Печалби

Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

13.89% нагоре

12-месечна прогноза

Среден 64.29 USD 13.89%

Висок 75 USD

Нисък 54 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 50.57Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

138 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.